Dyne Therapeutics (NASDAQ:DYN) Director Brian Posner Buys 2,000 Shares

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Brian Posner acquired 2,000 shares of the firm’s stock in a transaction on Tuesday, May 26th. The stock was purchased at an average price of $18.21 per share, for a total transaction of $36,420.00. Following the transaction, the director directly owned 20,000 shares of the company’s stock, valued at approximately $364,200. This trade represents a 11.11% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Dyne Therapeutics Price Performance

DYN stock opened at $18.56 on Friday. The firm’s 50-day moving average price is $18.27 and its two-hundred day moving average price is $18.31. Dyne Therapeutics, Inc. has a 12-month low of $8.06 and a 12-month high of $25.00. The stock has a market capitalization of $3.07 billion, a price-to-earnings ratio of -5.76 and a beta of 1.08. The company has a current ratio of 19.92, a quick ratio of 19.92 and a debt-to-equity ratio of 0.17.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.04. During the same quarter in the previous year, the firm posted ($1.05) earnings per share. As a group, equities analysts predict that Dyne Therapeutics, Inc. will post -3 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on DYN shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Monday, April 20th. Morgan Stanley reduced their price target on shares of Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating on the stock in a research report on Monday, March 2nd. Sanford C. Bernstein boosted their price target on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a research report on Wednesday, May 13th. HC Wainwright reduced their price target on shares of Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating on the stock in a research report on Tuesday, March 3rd. Finally, Chardan Capital reiterated a “buy” rating and set a $38.00 price target on shares of Dyne Therapeutics in a research report on Monday, March 9th. Three investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $35.00.

Institutional Investors Weigh In On Dyne Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of DYN. T. Rowe Price Investment Management Inc. grew its holdings in Dyne Therapeutics by 523.7% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company’s stock worth $343,085,000 after purchasing an additional 14,727,667 shares during the period. Orbis Allan Gray Ltd purchased a new stake in Dyne Therapeutics in the fourth quarter worth about $93,926,000. Adage Capital Partners GP L.L.C. purchased a new stake in Dyne Therapeutics in the second quarter worth about $30,378,000. Perceptive Advisors LLC grew its holdings in Dyne Therapeutics by 543.7% in the fourth quarter. Perceptive Advisors LLC now owns 3,478,944 shares of the company’s stock worth $68,048,000 after purchasing an additional 2,938,500 shares during the period. Finally, Marshall Wace LLP grew its holdings in Dyne Therapeutics by 572.9% in the third quarter. Marshall Wace LLP now owns 3,013,377 shares of the company’s stock worth $38,119,000 after purchasing an additional 2,565,570 shares during the period. Hedge funds and other institutional investors own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.